Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.

Oncogene - 31 Jan 2008

Nardi V, Raz T, Cao X, Wu C J, Stone R M, Cortes J, Deininger M W N, Church G, Zhu J, Daley G Q

Abstract excerpt

Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 17684485
DOI: 10.1038/sj.onc.1210698

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.PMID 17684485Read ↗

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.Semantic proximity Read ↗

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainSemantic proximity Read ↗

Detection and quantification of the abelson tyrosine kinase domains of the BCR-ABL gene translocation in chronic myeloid leukaemia using genomic quantitative real-time polymerase chain reaction.Semantic proximity Read ↗

Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment.Semantic proximity Read ↗

Development of an Integrated Assay for Detection of BCR-ABL RNASemantic proximity Read ↗

Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction.Semantic proximity Read ↗

Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.Semantic proximity Read ↗

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.Semantic proximity Read ↗

The use of the polymerase chain reaction in clinical oncology.Semantic proximity Read ↗

Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.Semantic proximity Read ↗

A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.Semantic proximity Read ↗

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.